Currently, there are 256.14M common shares owned by the public and among those 219.99M shares have been available to trade.
However, the script later moved the day high at 15.29, down -2.96%. The company’s stock has a 5-day price change of -5.23% and 69.37% over the past three months. IOVA shares are trading 69.37% year to date (YTD), with the 12-month market performance up to 123.90% higher. It has a 12-month low price of $3.21 and touched a high of $18.33 over the same period. IOVA has an average intraday trading volume of 9.71 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -8.36%, 11.00%, and 76.56% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares accounts for 67.26% of the company’s 256.14M shares outstanding.
It has a market capitalization of $3.85B and a beta (3y monthly) value of 0.59. The earnings-per-share (ttm) stands at -$1.89. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.93% over the week and 6.73% over the month.
Earnings per share for the fiscal year are expected to increase by 30.65%, and 41.97% over the next financial year.
Looking at the support for the IOVA, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on November 20, 2023, with the firm’s price target at $12. Barclays coverage for the Iovance Biotherapeutics Inc (IOVA) stock in a research note released on September 18, 2023 offered a Overweight rating with a price target of $18. Wells Fargo was of a view on May 30, 2023 that the stock is Overweight, while Wells Fargo gave the stock Equal Weight rating on March 27, 2023, issuing a price target of $11. Piper Sandler on their part issued Overweight rating on January 27, 2023.
